Cargando…
Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment
Autores principales: | Lv, Jialu, Lin, Jianqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152428/ https://www.ncbi.nlm.nih.gov/pubmed/33243960 http://dx.doi.org/10.4103/aja.aja_77_20 |
Ejemplares similares
-
Mathematical models in GnRH research
por: Voliotis, Margaritis, et al.
Publicado: (2022) -
Comparison of GnRH Agonist, GnRH Antagonist, and GnRH Antagonist Mild Protocol of Controlled Ovarian Hyperstimulation in Good Prognosis Patients
por: Stimpfel, Martin, et al.
Publicado: (2015) -
Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
por: Dun, Erica C., et al.
Publicado: (2017) -
A novel orally active gonadotropin‐releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology
por: Hamada, Michiko, et al.
Publicado: (2021) -
GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
por: Cota, Ana Marcia M, et al.
Publicado: (2012)